Retrovirus-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice

Gene Therapy

Volumn 6, Issue 11, 1999, Pages 1893-1897

  Sacco, M G ^a,d   Benedetti, S ^b   Mira Cato E ^a   Caniatti, M ^c   Ceruti, R ^c   Scanziani, E ^c   Pirola, B ^b   Villa, A ^a   Finocchiaro, G ^b   Vezzoni, P ^a  

^a CNR   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Ist Tecnologie Biomediche Avanzate   (Italy)

Author keywords

Cancer gene therapy; IL 4; Transgenic

Indexed keywords

INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CONTROLLED STUDY; FEMALE; GENE THERAPY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RETROVIRUS; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALIA; MAMMARY TUMOR ONCOVIRUS; MOUSE MAMMARY TUMOR VIRUS; MUS MUSCULUS; ONCOVIRINAE; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0032757532     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301017     Document Type: Article

References (25)

1. Hanahan D. Transgenic mice as probes into complex systems. Science 1989; 246: 1265-1275.
2. Pattengale PK et al. Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am J Pathol 1989; 135: 39-61.
3. Jacks T. Tumor suppressor gene mutations in mice. Annu Rev Genet 1996; 30: 603-636.
4. Sacco MG et al. Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirus-mediated HSVtk transfer in vivo. Gene Therapy 1996; 3: 1151-1156.
5. Sacco MG et al. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice. Gene Therapy 1998; 5: 388-393.
6. Sacco MG et al. Local regression of breast tumors following intrammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Therapy 1995; 2: 493-497.
7. Sacco MG et al. Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Res Treat 1998; 47: 171-180.
8. Lucchin F et al. Early and multifocal tumors in breast, salivary, harderian and epididimal tissues developed in MMTV-Neu transgenic mice. Cancer Lett 1992; 64: 203-209.
9. Boggio K et al. Interleukin-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/Neu transgenic mice. J Exp Med 1998; 188: 589-596.
10. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an E. coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
11. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolisis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997; 3: 639-645.
12. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
13. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-512.
14. Hoon DSB et al. Modulation of human melanoma cells by interleukin 4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res 1991; 51: 2002-2008.
15. Morisaki T et al. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. Cancer Res 1994; 54: 1113-1118.
16. Topp MS et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995; 55: 2173-2176.
17. Toi M, Bicknell R, Harris AL. Inibition of colon and breast carcinoma cell growth by interleukin 4. Cancer Res 1992; 52: 275-279.
18. Blais Y et al. Interleukin 4 and interleukin 13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol Cell Endocrinol 1996; 121: 11-18.
19. Gooch JL, Lee AV, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 1998; 58: 4199-4205.
20. Paillard F. Cancer cells under the fire of combined therapies. Hum Gene Ther 1998; 9: 1259-1260.
21. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-1870.
22. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T lymphocyte cross-talk. Cancer Res 1992; 52: 4853-4857.
23. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994; 153: 5659-5673.
24. Volpert O et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998; 188: 1039-1046.
25. Colombo BM et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mecliated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.